Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer

被引:15
作者
Liu, Xiaoran [1 ]
Ran, Ran [1 ]
Shao, Bin [1 ]
Rugo, Hope S. [2 ]
Yang, Yanlian [3 ]
Hu, Zhiyuan [3 ]
Wei, Zewen [3 ]
Wan, Fengling [1 ]
Kong, Weiyao [1 ]
Song, Guohong [1 ]
Jiang, Hanfang [1 ]
Liang, Xu [1 ]
Zhang, Ruyan [1 ]
Yan, Ying [1 ]
Xu, Guobing [4 ]
Li, Huiping [1 ]
机构
[1] Peking Univ, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Breast Oncol,Canc Hosp & Inst, Beijing 100142, Peoples R China
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94115 USA
[3] Chinese Acad Sci, Key Lab Standardizat & Measurement Nanotechnol, Natl Ctr Nanosci & Technol China, Beijing 100190, Peoples R China
[4] Peking Univ, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Clin Lab,Canc Hosp & Inst, Beijing 100142, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; nanotechnology; circulating tumor cell; immunology; MOLECULAR SUBTYPES; DENDRITIC CELLS; IMMUNE-SYSTEM; NK-CELLS; T-CELLS; EXPRESSION; BLOOD; PHENOTYPE;
D O I
10.21147/j.issn.1000-9604.2018.03.04
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Triple-negative breast cancer (TNBC) is a heterogeneous disease with poor prognosis. Circulating tumor cells (CTCs) are a promising predictor for breast cancer prognoses but their reliability regarding progression-free survival (PFS) is controversial. We aim to verify their predictive value in TNBC. Methods: In present prospective cohort study, we used the Pep@MNPs method to enumerate CTCs in baseline blood samples from 75 patients with TNBC (taken at inclusion in this study) and analyzed correlations between CTC numbers and outcomes and other clinical parameters. Results: Median PFS was 6.0 (range: 1.0-25.0) months for the entire cohort, in whom we found no correlations between baseline CTC status and initial tumor stage (P=0.167), tumor grade (P=0.783) or histological type (P=0.084). However, among those getting first-line treatment, baseline CTC status was positively correlated with ratio of peripheral natural killer (NK) cells (P=0.032), presence of lung metastasis (P=0.034) and number of visceral metastatic site (P=0.037). Baseline CTC status was predictive for PFS in first-line TNBC (P=0.033), but not for the cohort as a whole (P=0.118). This prognostic limitation of CTC could be ameliorated by combining CTC and NK cell enumeration (P=0.049). Conclusions: Baseline CTC status was predictive of lung metastasis, peripheral NK cell ratio and PFS in TNBC patients undergoing first-line treatment. We have developed a combined CTC-NK enumeration strategy that allows us to predict PFS in TNBC without any preconditions.
引用
收藏
页码:315 / +
页数:15
相关论文
共 44 条
  • [31] Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer.
    O'Shaughnessy, Joyce
    Osborne, Cynthia
    Pippen, John E.
    Yoffe, Mark
    Patt, Debra
    Rocha, Christine
    Koo, Ingrid Chou
    Sherman, Barry M.
    Bradley, Charles
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (03) : 205 - 214
  • [32] Dendritic Cells, Inflammation, and Breast Cancer
    Palucka, Karolina
    Coussens, Lisa M.
    O'Shaughnessy, Joyce
    [J]. CANCER JOURNAL, 2013, 19 (06) : 511 - 516
  • [33] Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
    Paoletti, Costanza
    Li, Yufeng
    Muniz, Maria C.
    Kidwell, Kelley M.
    Aung, Kimberly
    Thomas, Dafydd G.
    Brown, Martha E.
    Abramson, Vandana G.
    Irvin, William J., Jr.
    Lin, Nancy U.
    Liu, Minetta C.
    Nanda, Rita
    Nangia, Julie R.
    Storniolo, Anna M.
    Traina, Tiffany A.
    Vaklavas, Christos
    Van Poznak, Catherine H.
    Wolff, Antonio C.
    Forero-Torres, Andres
    Hayes, Daniel F.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2771 - 2779
  • [34] Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor-Positive Breast Cancer
    Paoletti, Costanza
    Muniz, Maria C.
    Thomas, Dafydd G.
    Griffith, Kent A.
    Kidwell, Kelley M.
    Tokudome, Nahomi
    Brown, Martha E.
    Aung, Kimberly
    Miller, M. Craig
    Blossom, Dorothy L.
    Schott, Anne F.
    Henry, N. Lynn
    Rae, James M.
    Connelly, Mark C.
    Chianese, David A.
    Hayes, Daniel F.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (11) : 2487 - 2498
  • [35] Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes
    Peeters, D. J. E.
    van Dam, P-J
    Van den Eynden, G. G. M.
    Rutten, A.
    Wuyts, H.
    Pouillon, L.
    Peeters, M.
    Pauwels, P.
    Van Laere, S. J.
    van Dam, P. A.
    Vermeulen, P. B.
    Dirix, L. Y.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 110 (02) : 375 - 383
  • [36] Platelet-Derived MHC Class I Confers a Pseudonormal Phenotype to Cancer Cells That Subverts the Antitumor Reactivity of Natural Killer Immune Cells
    Placke, Theresa
    Oergel, Melanie
    Schaller, Martin
    Jung, Gundram
    Rammensee, Hans-Georg
    Kopp, Hans-Georg
    Salih, Helmut Rainer
    [J]. CANCER RESEARCH, 2012, 72 (02) : 440 - 448
  • [37] Molecular Biomarker Analyses Using Circulating Tumor Cells
    Punnoose, Elizabeth A.
    Atwal, Siminder K.
    Spoerke, Jill M.
    Savage, Heidi
    Pandita, Ajay
    Yeh, Ru-Fang
    Pirzkall, Andrea
    Fine, Bernard M.
    Amler, Lukas C.
    Chen, Daniel S.
    Lackner, Mark R.
    [J]. PLOS ONE, 2010, 5 (09): : 1 - 12
  • [38] Rao CG, 2005, INT J ONCOL, V27, P49
  • [39] Subtypes of breast cancer show preferential site of relapse
    Smid, Marcel
    Wang, Yixin
    Zhang, Yi
    Sieuwerts, Anieta M.
    Yu, Jack
    Klijn, Jan G. M.
    Foekens, John A.
    Martens, John W. M.
    [J]. CANCER RESEARCH, 2008, 68 (09) : 3108 - 3114
  • [40] The metastasis-promoting roles of tumor-associated immune cells
    Smith, Heath A.
    Kang, Yibin
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 2013, 91 (04): : 411 - 429